Bionano Genomics, Inc.
BNGO
Health Care
2
exclusion reasons
1 theme
Bionano Genomics, Inc. is screened out under 2 exclusion reasons spanning 1 issue category.
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. It is a statement of values.
Bionano Genomics develops and sells optical genome mapping (OGM) systems and consumable kits used in genomic research. The company’s Saphyr system and associated kits are designed for the extraction and analysis of ultra-high molecular weight (UHMW) DNA from human and animal tissue samples, including tumors. This positions its core products as tools for animal testing and research.
According to its public filings, Bionano’s kits and protocols enable DNA extraction from animal tissue, a standard application in preclinical and biomedical research. The company’s technology is marketed to research and clinical laboratories, which routinely use animal models. While the specific scale of animal use facilitated by Bionano’s products is not publicly quantified, the company’s business model is built on supplying equipment and consumables for genomic analysis, a field reliant on animal testing. No public commitment to developing or promoting non-animal alternative methods was found in the provided materials.
Bionano Genomics develops and sells optical genome mapping systems and software used in cytogenetics research and clinical laboratories. The company’s Saphyr system and VIA software are genomic analysis tools designed for applications in cancer research, genetic disease diagnosis, and drug development. These tools are used by researchers in academic, pharmaceutical, and clinical settings, many of whom conduct animal testing as part of their experimental workflows to validate genomic findings or develop therapies.
The company’s products and services are integral to preclinical research pipelines that rely on animal models. For example, Bionano’s technology has been cited in published studies analyzing DNA from animal models of disease, and its systems are used in contract research organizations and academic labs conducting such animal-based experiments. By providing the core instrumentation and analysis software for these studies, Bionano enables and profits from animal testing conducted by its customers. The company’s business model is built on serving the research market, where animal testing remains a standard regulatory and developmental requirement for genomic medicine.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.